Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

NCT00683904 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
DRUG: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL

Sponsor

R-Pharm